Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.

Lee JJ, Huang J, England CG, McNally LR, Frieboes HB.

PLoS Comput Biol. 2013;9(9):e1003231. doi: 10.1371/journal.pcbi.1003231. Epub 2013 Sep 19.

2.

Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.

Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H.

Int J Cancer. 2004 Mar 20;109(2):182-8.

3.

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.

Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA.

BMC Cancer. 2015 Feb 19;15:71. doi: 10.1186/s12885-015-1064-9.

4.

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.

Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M.

Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.

5.
6.

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.

Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.

Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. Epub 2005 Jun 10.

PMID:
15947928
7.

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.

Hong SP, Wen J, Bang S, Park S, Song SY.

Int J Cancer. 2009 Nov 15;125(10):2323-31. doi: 10.1002/ijc.24573.

8.

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.

9.

Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.

Chen D, Niu M, Jiao X, Zhang K, Liang J, Zhang D.

Int J Mol Sci. 2012;13(1):1186-208. doi: 10.3390/ijms13011186. Epub 2012 Jan 20.

10.

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.

Namba T, Kodama R, Moritomo S, Hoshino T, Mizushima T.

Cell Death Dis. 2015 Jun 25;6:e1795. doi: 10.1038/cddis.2015.172.

11.

Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.

Chen H, Wei W, Guo Y, Liu A, Tong H, Wang Z, Tan W, Liu J, Lin S.

Oncol Rep. 2011 May;25(5):1253-61. doi: 10.3892/or.2011.1174. Epub 2011 Feb 3.

PMID:
21305255
12.

Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.

Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Tomonaga T, Nomura F, Miyazaki M.

Ann Surg Oncol. 2008 Nov;15(11):3157-68. doi: 10.1245/s10434-008-0061-5. Epub 2008 Aug 20.

PMID:
18712570
13.

K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.

Réjiba S, Wack S, Aprahamian M, Hajri A.

Cancer Sci. 2007 Jul;98(7):1128-36. Epub 2007 May 8.

14.

Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.

Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK.

Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.

15.
16.

[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].

Kreil A, Bauer J, Scheithauer W.

Acta Med Austriaca. 1999;26(3):93-100. German.

PMID:
10520377
17.

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.

Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.

Cancer Immunol Immunother. 2014 Apr;63(4):321-33. doi: 10.1007/s00262-013-1510-y. Epub 2014 Jan 3.

PMID:
24384835
18.

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.

Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD.

Clin Cancer Res. 2008 Dec 15;14(24):8143-51. doi: 10.1158/1078-0432.CCR-08-1539.

19.

Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.

Hu G, Li F, Ouyang K, Xie F, Tang X, Wang K, Han S, Jiang Z, Zhu M, Wen D, Qin X, Zhang L.

Int J Oncol. 2012 Mar;40(3):798-806. doi: 10.3892/ijo.2011.1254. Epub 2011 Nov 7.

PMID:
22076649
20.

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.

Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM.

Int J Cancer. 2002 Nov 10;102(2):101-8.

Supplemental Content

Support Center